Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Daily News Briefs

Photonics.com
Aug 2005
Corning Inc. has been granted a license for patent rights to reverse transfection method technology for the drug discovery research market by the Whitehead Institute for Biomedical Research, through Massachusetts Institute of Technology (MIT), its licensing agent. Corning will use the intellectual property with fundamental technology it previously licensed from Aastrom Biosciences Inc. to enhance the development of its molecular and cell culture applications. Corning holds exclusive rights to Aastrom's surface-mediated cell transfection technology, used to increase the frequency and efficiency of introducing foreign genes into cells.

BiophotonicsCorningMassachusetts Institute of TechnologyNews BriefsPhotonics Tech BriefsWhitehead Institute for Biomedical Research

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x We deliver – right to your inbox. Subscribe FREE to our newsletters.